Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Sell
31
HRTX Quote, Financials, Valuation and Earnings
Last price:
$1.55
Seasonality move
:
1.16%
Day range:
$1.52 - $1.60
52-week range:
$1.04 - $3.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.71x
P/B ratio:
--
Volume:
1.1M
Avg. volume:
4.6M
1-year change:
-30.34%
Market cap:
$235.7M
Revenue:
$127M
EPS (TTM):
-$0.16
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Heron Therapeutics has 287.1% upside to fair value with a price target of -- per share.
HRTX vs. S&P 500
-
Over the past 5 trading days, Heron Therapeutics has underperformed the S&P 500 by -1.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Heron Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Heron Therapeutics has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Heron Therapeutics reported revenues of $32.8M.
Earnings Growth
-
Heron Therapeutics earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Heron Therapeutics reported earnings per share of -$0.03.
Enterprise value:
339.3M
EV / Invested capital:
--
Price / LTM sales:
1.71x
EV / EBIT:
--
EV / Revenue:
2.46x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-35.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$99.4M
Return On Assets:
-12.62%
Net Income Margin (TTM):
-20.31%
Return On Equity:
--
Return On Invested Capital:
-20.08%
Operating Margin:
-13.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $98.3M | $122.8M | $137.7M | $31.4M | $32.8M | |
| Gross Profit | $45.1M | $55M | $99.4M | $13.2M | $23.4M | |
| Operating Income | -$207.8M | -$120.8M | -$25.9M | -$24.9M | -$4.5M | |
| EBITDA | -$205.4M | -$122.7M | -$19.4M | -$24.2M | -$3.9M | |
| Diluted EPS | -$2.10 | -$0.96 | -$0.16 | -$0.17 | -$0.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $351M | $315.1M | $223.8M | $194M | $195.2M | |
| Total Assets | $390M | $352.4M | $272M | $229.2M | $220.8M | |
| Current Liabilities | $97.6M | $72.3M | $93.9M | $79.7M | $85.5M | |
| Total Liabilities | $112.9M | $233.5M | $249.5M | $257M | $260.8M | |
| Total Equity | $277.1M | $118.8M | $22.5M | -$27.8M | -$40M | |
| Total Debt | $6.6M | $149M | $149.2M | $173.5M | $174.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$154.6M | -$98.8M | -$8.3M | -$9.2M | $3.4M | |
| Cash From Investing | -$29.6M | $28.9M | -$1.5M | -$23.2M | $4M | |
| Cash From Financing | $75.1M | $54.3M | $716K | $53.8M | $14K | |
| Free Cash Flow | -$156.4M | -$100.5M | -$9.6M | -$10M | $2.9M | |
HRTX
Sector
Market Cap
$235.7M
$47.5M
Price % of 52-Week High
39.44%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-30.34%
-34.04%
Beta (5-Year)
1.602
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.62
200-day SMA
Sell
Level
$2.35
Bollinger Bands (100)
Sell
Level
1.44 - 1.98
Chaikin Money Flow
Sell
Level
-33.1M
20-day SMA
Sell
Level
$1.61
Relative Strength Index (RSI14)
Sell
Level
48.19
ADX Line
Buy
Level
29.06
Williams %R
Neutral
Level
-75.6757
50-day SMA
Buy
Level
$1.52
MACD (12, 26)
Buy
Level
0.03
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
61.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-11.8179)
Sell
CA Score
(Annual)
Level (-4.7799)
Buy
Beneish M-Score
(Annual)
Level (-3.6539)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (6.7631)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Stock Forecast FAQ
In the current month, HRTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The HRTX average analyst price target in the past 3 months is --.
-
Where Will Heron Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Heron Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Heron Therapeutics?
Analysts are divided on their view about Heron Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Heron Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Heron Therapeutics's Price Target?
The price target for Heron Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is HRTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Heron Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of HRTX?
You can purchase shares of Heron Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Heron Therapeutics shares.
-
What Is The Heron Therapeutics Share Price Today?
Heron Therapeutics was last trading at $1.55 per share. This represents the most recent stock quote for Heron Therapeutics. Yesterday, Heron Therapeutics closed at $1.55 per share.
-
How To Buy Heron Therapeutics Stock Online?
In order to purchase Heron Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
